More recently, the CAPITAIN study showed that 6-month treatment with pitavastatin 4 mg did not significantly change the mean FPG, homeostasis model assessment index, insulin levels, insulin/glucose ratios, or HbA1c levels in people with metabolic syndrome [30]. The gene discussed is INS; the disease is metabolic syndrome.